Onconova Medical Onconova Therapeutics, Inc. (NASDAQ:ONTX) was founded in 1998 and listed on NASDAQ in July 2013 with an IPO. Headquartered in Newtown, Pennsylvania, USA, with 25 full-time employees, it is a clinical-stage biopharmaceutical company. Focus on the discovery and development of small molecule candidate products for the treatment of cancer.
Onconova Therapeutics (ONTX):
Onconova Therapeutics, Inc. is a phase III clinical biopharmaceutical company focusing on the discovery and development of new small molecule drug candidates for the treatment of cancer. Using a proprietary chemical platform, Onconova has created a series of targeted anti-cancer agents designed to disrupt specific cellular pathways that are essential for cancer cell proliferation. Onconova has III product candidates and several preclinical projects in clinical trials.
Advanced clinical trials of Onconova Therapeutics’ lead compound rigosertib are aimed at the unmet medical needs of patients with myelodysplastic syndrome (MDS). MDS is a hematological malignant tumor that causes bone marrow failure, leading to acute myeloid leukemia (AML) in 30% of high-risk patients. For more than 10 years, this research has made no progress. Current treatment options are not curative and often cause serious side effects. There are more than 10,000 MDS patients in the United States, all of which are unmet medical needs.
Onconova Therapeutics product candidates:
- Rigosertib IV, the drug is in phase III clinical trials for patients with high-risk myelodysplastic syndrome (MDS); Rigosertib oral preparations are in phase II clinical trials in combination with azacitidine for the treatment of high-risk MDS; Rigosertib oral preparations are still in Phase II clinical trial for the treatment of low-risk MDS.
- The company also developed Bririclib, a phase I multipoint dose escalation trial for patients with advanced solid tumors.
- Recilisib has completed four phase I clinical trials for patients with acute radiation syndrome.
- In addition, Onconova Therapeutics has various product candidates for kinases, cell metabolism or cell division in pre-clinical development.
Onconova Therapeutics has signed a license agreement with SymBio Pharmaceuticals Limited; signed a development and license agreement with Baxter Healthcare SA; signed a license, development and commercialization agreement with Pint International SA; signed a license and cooperation agreement with HanX Biopharmaceuticals, Inc.